Processa Pharmaceuticals, Inc. Total Shareholder Rtn Amt
Processa Pharmaceuticals, Inc. (PCSA) reported Total Shareholder Rtn Amt of $2 for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-06-18.
Financial Statements › Notes
ecd:TotalShareholderRtnAmt · last filed 2026-06-18
| Period end | Total Shareholder Rtn Amt 12 month |
|---|---|
| 2025-12-31 | $2.00 DEF 14A · filed 2026-06-18 |
| 2024-12-31 | $13.00 DEF 14A · filed 2026-06-18 |
| 2023-12-31 | $100.00 DEF 14A · filed 2026-06-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |